OBJECTIVE： To observe clinical efficacy and safety of Shuxuetong injection combined with alprostadil in the treatment of acute cerebral infraction （ACI）. METHODS： A total of 123 ACI patients selected from our hospital during Mar. 2014-Sept. 2016 selected as research subjects were divided into observation group （62 cases） and control group （61 cases） according to random number table. Control group was additionally given Alprostadil injection 2 mL+0.9％ Sodium chloride injection 100 mL， ivgtt， qd， on the basis of routine treatment. Observation group was additionally given Shuxuetong injection 6 mL+0.9％ Sodium chloride injection 250 mL， ivgtt， qd， on the basis of control group. Both groups were treated for 2 weeks. MPV， FIB content， hemorheology indexes， neurologic impairment degree score before and after treatment as well as clinical efficacy， the occurrence of ADR were compared between 2 groups. RESULTS： Before treatment， there was no statistical significance in MPV， FIB content， hemorheology indexes or neurologic impairment score between 2 groups （P＞0.05）. Compared with before treatment， MPV， FIB content， hemorheology indexes and modified Rankin scale of 2 groups were all decreased significantly； Barthel index and NIHSS scores were increased significantly， and each aspect of observation group was better than that of control group， with statistical significance （P＜0.05）. Total response rate of observation group was 95.16％， which was significantly higher than 85.25％ of control group， with statistical significance （P＜0.05）. No severe ADR was found in 2 groups. CONCLUSIONS： Shuxuetong injection combined with alprostadil can significantly improve the neurological function of ACI patients， improve hypercoagulable state by reducing MPV and FIB content， and have good therapeutic efficacy and safety.